From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

BREAKING: Shield Therapeutics IS the next Omega, a short at 25.5p - target 5.5p

By Tom Winnifrith, the Sheriff of AIM | Friday 18 February 2022

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Shield Therapeutics (STX) has the status Omega Diagnostics (ODX) once had as a darling of the Bulletin Board savants. And like Omega was this company is heading for a cash crisis and its shares will tank by 80%. Though this will enrage a shareholder base with the collective IQ of a cheese sandwich, the shares are a stand out short at 25.5p with a 5.5p target.  Chaps and gals ,before you start the hate attacks on me learn from the Omega debacle HERE. Now as to why Shield shares will collapse, here’s why.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Video: Poking Bears And Black Swans



Is Stuart Ashman lying again?



So farewell then

Time left: 21:37:11